Data presented at ESMO “provides strong evidence for an enhanced anti-cancer effect with the combination” of Pluvicto and Xtandi, according to one expert.
There was continued uptake of the CDK4/6 inhibitor among breast cancer patients, and the Swiss drugmaker resolved supply shortages for the prostate cancer radiopharmaceutical Pluvicto.
/PRNewswire/ The global nanomedicine market size is expected to reach USD 410.15 billion by 2030, expanding at 11.57% CAGR from 2023 to 2030, according to a.
/PRNewswire/ - The global nuclear medicine market size is expected to reach USD 22.3 billion by 2030, registering a CAGR of 11.8% over the forecast period,.
/PRNewswire/ The global complementary and alternative medicine market size is expected to reach USD 694.22 billion by 2030 and is expected to expand at.